OBJECTIVE: To explore the effects of Chaihu Guizhi Ganjiang Decoction combined with standard triple therapy on treating H.pylori-related gastritis. METHODS: Eighty-two patients with H. pylori-related gastritis treated...OBJECTIVE: To explore the effects of Chaihu Guizhi Ganjiang Decoction combined with standard triple therapy on treating H.pylori-related gastritis. METHODS: Eighty-two patients with H. pylori-related gastritis treated in our hospital from January 2016 to December 2017 were selected according to the random number table method and divided into experimental group and control group, with 41 patients in each group. The control group was treated with standard triple therapy, while the experimental group was additionally treated with modified Chaihu Guizhi Ganjiang Decoction. The venous blood of one elbow was taken before and after treatment. The concentrations of serum CagA and Hp-NAP were detected by enzyme-linked immunosorbent assay(ELISA). The symptoms were evaluated according to the change of symptom scores before and after the intervention. The H.pylori eradication rate was calculated. RESULTS: There was no significant difference in CagA and Hp-NAP concentrations between the 2 groups before intervention(P > 0.05). After intervention, CagA and Hp-NAP concentrations in experimental group were(19.21±6.27) ng/L and(24.37±6.10) ng/L respectively which were lower than(25.81±7.14) ng/L and(32.09±5.73) ng/L of control group. The differences were statistically significant(P < 0.05). The total effective rate of major symptoms in experimental group was 39 cases(95.12%), which was significantly higher than that of the control group(31 cases, 75.61%). There was statistically significant difference between the 2 groups(P < 0.05). The eradication rate of H.pylori was 38 cases(92.68%) in the experimental group, which was significantly higher than 31 cases(75.61%) of the control group. The difference between the 2 groups was statistically significant(P < 0.05). CONCLUSION: Chaihu Guizhi Ganjiang Decoction combined with standard triple therapy can effectively reduce CagA, Hp-NAP of serum level in patients with H.pylori-related gastritis, improve efficacy of symptoms and eradication rate of H.pylori, and is worthy of clinical promotion.展开更多
目的:基于网络药理学探讨柴胡桂枝干姜汤治疗腺样体肥大的作用机制。方法:通过中药系统药理学数据库与分析平台(traditional Chinese medicine systems pharmacology database and analysis platform,TCMSP),BATMAN-TCM数据库结合口服...目的:基于网络药理学探讨柴胡桂枝干姜汤治疗腺样体肥大的作用机制。方法:通过中药系统药理学数据库与分析平台(traditional Chinese medicine systems pharmacology database and analysis platform,TCMSP),BATMAN-TCM数据库结合口服利用度(oral bioavailability,OB)、类药性(drug-likeness,DL),药物半衰期(drug half-life,HL)检索柴胡桂枝干姜汤中柴胡、桂枝、干姜、黄芩、瓜蒌根、牡蛎、炙甘草的候选化合物及作用靶点信息,并通过Uniprot数据库将靶点校正为基因名;运用Genecards数据库获取腺样体肥大的相关靶点与基因,利用VENNY图获得柴胡桂枝干姜汤与腺样体肥大的交集靶点;STRING数据库来构建蛋白质相互作用PPI网络图;David数据库对交集靶点进行基因本体(gene ontology,GO)功能富集分析和KEGG通路富集分析;Cytoscape软件进行网络靶点特性分析。结果:筛选出柴胡桂枝干姜汤候选化合物65个,转化为有效靶点288个,得到腺样体肥大相关靶点781个,匹配得到共有靶点118个。GO富集主要涉及597个生物学过程、60个细胞组成和106个分子功能,KEGG通路分析主要涉及112条通路。结论:柴胡桂枝干姜汤治疗腺样体肥大是通过多靶点多通路发挥作用的。展开更多
目的:采用Meta分析系对柴胡桂枝干姜汤治疗腹泻型肠易激综合征的有效性及安全性进行再评价,为临床提供循证依据。方法:检索万方、CNKI、CBM、VIP、PubMed、Web of Science数据库,提取采用柴胡桂枝干姜汤加减治疗腹泻型肠易激综合征的随...目的:采用Meta分析系对柴胡桂枝干姜汤治疗腹泻型肠易激综合征的有效性及安全性进行再评价,为临床提供循证依据。方法:检索万方、CNKI、CBM、VIP、PubMed、Web of Science数据库,提取采用柴胡桂枝干姜汤加减治疗腹泻型肠易激综合征的随机对照试验临床研究文献。提取文献的相关原始数据,通过Meta分析对柴胡桂枝干姜汤加减治疗腹泻型肠易激综合征的临床治愈率、临床总有效率、复发率、不良反应发生率、IBS-SSS和IBS-QOL等指标进行统计分析。结果:Meta分析结果表明,与西药相比,柴胡桂枝干姜汤加减治疗腹泻型肠易激综合征临床治愈率[RR=1.91,95%CI=(1.41,2.59),P<0.0001]和临床总有效率[RR=1.27,95%CI=(1.18,1.36),P<0.00001]更佳,且复发率更低[RR=0.18,95%CI=(0.05,0.62),P=0.007],对IBS-SSS[SMD=-4.44,95%CI=(-6.46,-2.41),P<0.0001]的改善作用更显著,改善IBS-QOL[SMD=0.54,95%CI=(-0.64,1.72),P=0.37]效果相当,两者均未出现显著不良反应。结论:与西药比较,柴胡桂枝干姜汤治疗腹泻型肠易激综合征,具有更好的临床效果,且复发率较低,副作用少,IBS-SSS、IBS-QOL症状明显改善,具有一定的临床应用价值。展开更多
文摘OBJECTIVE: To explore the effects of Chaihu Guizhi Ganjiang Decoction combined with standard triple therapy on treating H.pylori-related gastritis. METHODS: Eighty-two patients with H. pylori-related gastritis treated in our hospital from January 2016 to December 2017 were selected according to the random number table method and divided into experimental group and control group, with 41 patients in each group. The control group was treated with standard triple therapy, while the experimental group was additionally treated with modified Chaihu Guizhi Ganjiang Decoction. The venous blood of one elbow was taken before and after treatment. The concentrations of serum CagA and Hp-NAP were detected by enzyme-linked immunosorbent assay(ELISA). The symptoms were evaluated according to the change of symptom scores before and after the intervention. The H.pylori eradication rate was calculated. RESULTS: There was no significant difference in CagA and Hp-NAP concentrations between the 2 groups before intervention(P > 0.05). After intervention, CagA and Hp-NAP concentrations in experimental group were(19.21±6.27) ng/L and(24.37±6.10) ng/L respectively which were lower than(25.81±7.14) ng/L and(32.09±5.73) ng/L of control group. The differences were statistically significant(P < 0.05). The total effective rate of major symptoms in experimental group was 39 cases(95.12%), which was significantly higher than that of the control group(31 cases, 75.61%). There was statistically significant difference between the 2 groups(P < 0.05). The eradication rate of H.pylori was 38 cases(92.68%) in the experimental group, which was significantly higher than 31 cases(75.61%) of the control group. The difference between the 2 groups was statistically significant(P < 0.05). CONCLUSION: Chaihu Guizhi Ganjiang Decoction combined with standard triple therapy can effectively reduce CagA, Hp-NAP of serum level in patients with H.pylori-related gastritis, improve efficacy of symptoms and eradication rate of H.pylori, and is worthy of clinical promotion.
文摘目的:基于网络药理学探讨柴胡桂枝干姜汤治疗腺样体肥大的作用机制。方法:通过中药系统药理学数据库与分析平台(traditional Chinese medicine systems pharmacology database and analysis platform,TCMSP),BATMAN-TCM数据库结合口服利用度(oral bioavailability,OB)、类药性(drug-likeness,DL),药物半衰期(drug half-life,HL)检索柴胡桂枝干姜汤中柴胡、桂枝、干姜、黄芩、瓜蒌根、牡蛎、炙甘草的候选化合物及作用靶点信息,并通过Uniprot数据库将靶点校正为基因名;运用Genecards数据库获取腺样体肥大的相关靶点与基因,利用VENNY图获得柴胡桂枝干姜汤与腺样体肥大的交集靶点;STRING数据库来构建蛋白质相互作用PPI网络图;David数据库对交集靶点进行基因本体(gene ontology,GO)功能富集分析和KEGG通路富集分析;Cytoscape软件进行网络靶点特性分析。结果:筛选出柴胡桂枝干姜汤候选化合物65个,转化为有效靶点288个,得到腺样体肥大相关靶点781个,匹配得到共有靶点118个。GO富集主要涉及597个生物学过程、60个细胞组成和106个分子功能,KEGG通路分析主要涉及112条通路。结论:柴胡桂枝干姜汤治疗腺样体肥大是通过多靶点多通路发挥作用的。
文摘目的:采用Meta分析系对柴胡桂枝干姜汤治疗腹泻型肠易激综合征的有效性及安全性进行再评价,为临床提供循证依据。方法:检索万方、CNKI、CBM、VIP、PubMed、Web of Science数据库,提取采用柴胡桂枝干姜汤加减治疗腹泻型肠易激综合征的随机对照试验临床研究文献。提取文献的相关原始数据,通过Meta分析对柴胡桂枝干姜汤加减治疗腹泻型肠易激综合征的临床治愈率、临床总有效率、复发率、不良反应发生率、IBS-SSS和IBS-QOL等指标进行统计分析。结果:Meta分析结果表明,与西药相比,柴胡桂枝干姜汤加减治疗腹泻型肠易激综合征临床治愈率[RR=1.91,95%CI=(1.41,2.59),P<0.0001]和临床总有效率[RR=1.27,95%CI=(1.18,1.36),P<0.00001]更佳,且复发率更低[RR=0.18,95%CI=(0.05,0.62),P=0.007],对IBS-SSS[SMD=-4.44,95%CI=(-6.46,-2.41),P<0.0001]的改善作用更显著,改善IBS-QOL[SMD=0.54,95%CI=(-0.64,1.72),P=0.37]效果相当,两者均未出现显著不良反应。结论:与西药比较,柴胡桂枝干姜汤治疗腹泻型肠易激综合征,具有更好的临床效果,且复发率较低,副作用少,IBS-SSS、IBS-QOL症状明显改善,具有一定的临床应用价值。
